SCHEMBL483359

SCHEMBL483359

CCCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)CC(C)=O

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 20/20 0.65
TLR8 Q9NR97 7/20 0.65
NUDT1 P36639 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30346049 1.00 TLR7 (0.65) TLR7TLR8NUDT1
SCHEMBL24183879 0.87 TLR7 (0.76) TLR7TLR8
SCHEMBL5618061 0.85 TLR7 (0.60) TLR7TLR8NUDT1
SCHEMBL5618059 0.85 TLR7 (0.60) TLR7TLR8NUDT1
SCHEMBL5617101 0.85 TLR7 (0.67) TLR7TLR8NUDT1
SCHEMBL4140835 0.85 TLR7 (0.59) TLR7TLR8NUDT1
SCHEMBL29639778 0.85 TLR7 (0.87) TLR7TLR8NUDT1
SCHEMBL22512634 0.85 TLR7 (0.87) TLR7TLR8NUDT1
SCHEMBL30851461 0.84 TLR7 (0.65) TLR7TLR8NUDT1
SCHEMBL22898753 0.83 TLR7 (0.70) TLR7TLR8NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765071-B2 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-09-19 US claimed
US-20160194322-A1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2016-07-07 US claimed
EP-1687307-B1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2016-01-06 EP claimed
US-20140194628-A1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-07-10 US claimed
US-20250152703-A1 COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-15 US disclosed
US-12201684-B2 Compositions for stimulation of mammalian innate immune resistance to pathogens THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-01-21 US disclosed
US-20240417738-A1 IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER OHIO STATE INNOVATION FOUNDATION 2024-12-19 US disclosed
CN-110234401-B Methods and compositions for adaptive immunomodulation 德克萨斯大学系统董事会 2024-03-01 CN disclosed
US-20240033348-A1 METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION Pulmotect, Inc. 2024-02-01 US disclosed
US-11826422-B2 Methods and compositions for adaptive immune modulation BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-28 US disclosed
WO-2023070132-A1 IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER OHIO STATE INNOVATION FOUNDATION (US) 2023-04-27 WO disclosed
US-20200345842-A1 COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-11-05 US disclosed
US-20070099901-A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-03 US disclosed
US-20070072893-A1 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY 2007-03-29 US disclosed
US-20070072893-A1 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY 2007-03-29 US disclosed
US-20070072893-A1 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY 2007-03-29 US disclosed
EP-1687307-A2 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M Innovative Properties Company (US) 2006-08-09 EP disclosed
EP-1686992-A2 HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2006-08-09 EP disclosed
WO-2005051324-A2 HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-09 WO disclosed
WO-2005051317-A2 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072893-A1 Substituted imidazo ring systems and methods IL2, IRF3, EIF2AK2 TLR7 162/4885TLR8 131/4885NUDT1 1793/4885
US-20160194322-A1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS IL2, IRF3, EIF2AK2 TLR7 155/4885TLR8 137/4885NUDT1 1387/4885
US-20140194628-A1 SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS IL2, IRF3, EIF2AK2 TLR7 155/4885TLR8 137/4885NUDT1 1387/4885
US-20070099901-A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines IFNG, IRF3, IDO1 TLR7 81/4885TLR8 184/4885NUDT1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.